What caused ATNM's earnings surprise in Q4 2022?

Actinium Pharmaceuticals' (ATNM) earnings surprise in Q4 2022 was negative, with an EPS surprise of -0.08, indicating that the company's actual diluted EPS was lower than analysts' expectations. The total revenue for the quarter was $0, which also contributed to the negative surprise.

|code|Ticker|Name|Date|Revenue Surprise|Total Revenue|EPS Surprise|Diluted EPS|market_code|
|---|---|---|---|---|---|---|---|---|
|ATNM|ATNM.A|Actinium|2022 Q1||940000||-0.23|170|
|ATNM|ATNM.A|Actinium|2022 Q2||45000||-0.33|170|
|ATNM|ATNM.A|Actinium|2022 Q3||45000||-0.38|170|
|ATNM|ATNM.A|Actinium|2022 Q4|-1030000|0|-0.08||170|

The reasons for ATNM's disappointing financial results in Q4 2022 can be attributed to several factors:

1. **Delayed Phase 3 Data Release**: Actinium had initially expected to release detailed data from its late-stage SIERRA trial by the end of the year. However, the company had to postpone this release, leading to a potential delay for a Phase 3 readout for its lead product candidate, Iomab-B. This delay likely impacted the company's financial results for the quarter.
2. **Clinical Trial Updates**: Despite the delay in releasing detailed data, Actinium continued to make progress in its clinical trials. The company highlighted high rates of Complete Remission (CR/CRi) and measurable residual disease (MRD) negativity with improved overall survival in its Actimab-A CLAG-M combination trial in high-risk patients with relapsed or refractory acute myeloid leukemia (AML). However, these positive developments may not have been enough to offset the impact of the delayed data release on the company's financial performance in Q4 2022.

In conclusion, Actinium Pharmaceuticals' (ATNM) earnings surprise in Q4 2022 was primarily caused by a combination of delayed clinical data release and lower-than-expected revenue, despite positive clinical trial updates.